Hims & Hers Health (HIMS) Set to Post Earnings on Monday

Key Points

• Hims & Hers Health is expected to report Q3 2026 results after Monday’s market close. Analysts forecast earnings of approximately $0.06 per share and revenue of $892.88 million.
• The company’s previous quarter included a significant EPS miss, though revenue rose 38.2% year over year to $753.21 million. Analysts expect a full-year loss of $0.16 per share before profitability of $0.44 per share next year.
• Investor sentiment remains cautious: HIMS shares are down 0.3%, insiders have sold about 133,905 shares over the past quarter, and analysts’ consensus rating is “Hold” with an average price target of $32.43.

Hims & Hers Health (NYSE:HIMS - Get Free Report) is anticipated to announce its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect Hims & Hers Health to post earnings of $0.0566 per share and revenue of $892.88 million for the quarter. Individuals can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 5:00 PM ET.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. During the same period in the prior year, the company posted $0.17 earnings per share. The business's revenue was up 38.2% on a year-over-year basis. On average, analysts expect Hims & Hers Health to post ($0.16) EPS for the current fiscal year and $0.44 EPS for the next fiscal year.

Hims & Hers Health Stock Down 0.3%

HIMS stock opened at $27.59 on Monday. The firm has a market cap of $6.44 billion, a PE ratio of -43.79 and a beta of 2.53. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $48.34. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The firm has a 50 day simple moving average of $29.04 and a 200 day simple moving average of $27.08.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the business's stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $28.39, for a total value of $398,226.53. Following the sale, the chief operating officer owned 456,660 shares of the company's stock, valued at $12,964,577.40. The trade was a 2.98% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 3,462 shares of the stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $27.60, for a total transaction of $95,551.20. Following the completion of the transaction, the insider owned 293,886 shares of the company's stock, valued at approximately $8,111,253.60. This represents a 1.16% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 133,905 shares of company stock valued at $3,826,977. 11.76% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on HIMS shares. Weiss Ratings reissued a "sell (d)" rating on shares of Hims & Hers Health in a research note on Friday, August 7th. JPMorgan Chase & Co. initiated coverage on shares of Hims & Hers Health in a research note on Friday, September 11th. They issued a "neutral" rating and a $32.00 price objective for the company. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a "hold" rating in a report on Tuesday, August 11th. Wall Street Zen raised Hims & Hers Health from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Finally, Morgan Stanley raised their target price on Hims & Hers Health from $21.00 to $28.00 and gave the company an "equal weight" rating in a report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $32.43.

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.

Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.